RGT — Argent BioPharma Cashflow Statement
0.000.00%
Last trade - 00:00- AU$6.35m
- AU$5.69m
- AU$0.18m
Annual cashflow statement for Argent BioPharma, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Changes in Working Capital | -3.32 | -4.24 | -1.9 | -2.54 | -3.3 |
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -12 | -12.2 | -12 | -14.7 | -9.28 |
| Capital Expenditures | -3.33 | -2.69 | -0.19 | -0.14 | -0.002 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 1.83 | 1.58 | 0.796 | — | 0.211 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.49 | -1.11 | 0.606 | -0.14 | 0.209 |
| Financing Cash Flow Items | -1.2 | -0.703 | -0.102 | -0.437 | -0.568 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 17.1 | 9.74 | 9.73 | 15.3 | 9.39 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 3.56 | -3.55 | -1.65 | 0.463 | 0.322 |